Mississippi recibirá más de 771.000 dólares como parte de un acuerdo multiestatal con Abbott Laboratories. La Fiscal General Lynn Fitch dice que el acuerdo resuelve las acusaciones de que Abbott vendió fórmula infantil y productos nutricionales fabricados en condiciones que no cumplían con los estándares de seguridad mientras esos productos se pagaban a través de programas de salud gubernamentales. Abbott pagará más de 348 millones de dólares en todo el país para...

Abbott Laboratories will pay nearly $385 million to settle allegations that WIC and Medicaid paid for infant formula that failed federal standards.

Markets are back to obsessing over central bank signals, supply routes and growth downgrades, and that mix is shaking up how investors look at reliable income. When credit feels tighter and headlines keep flagging disruption risks, steady dividend cheques from global healthcare stocks can suddenly look more interesting. This piece walks through three healthcare dividend payers from our screener that appear closely exposed to the latest macro news and explains why their stories might matter to...

A secretary at an Illinois pharmaceutical company made a single, unremarkable stock purchase in 1935 and then did almost nothing for the next 75 years. What her college discovered when she died would quietly rewrite everything anyone thought they knew about her.

Detailed price information for Acurx Pharmaceuticals Inc (ACXP-Q) from The Globe and Mail including charting and trades.

Revenue rose 13.00 percent in the second quarter of 2026. Abbott Laboratories stock costs EUR 87.41

Intuitive Surgical is beating estimates and raising margins while its installed base keeps expanding. Abbott is executing steadily across a diversified portfolio but growing at a more measured pace.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Federal officials announced this week that a Fortune 500 healthcare devices and medical supplies company has agreed to pay just shy of $385 million to resolve allegations involving issues with its production of baby formula. The case stemmed from a November 2025 complaint alleging that Abbott Laboratories had caused federal government programs to purchase […]

Abbott Laboratories has seen its share price retreat over the past year, which puts the spotlight squarely on whether the current market value lines up with the cash the business is expected to generate. For investors already holding Abbott stock or thinking about starting a position, the question now is how well the recent share price reflects those cash flows. The share price has fallen 22.9% over the past year, which raises the issue of whether the recent slide has brought the valuation...

Abbott Laboratories (ABT) expanded its presence in cancer screening with the launch of SimpleScreen CRC in the US. The test is an FDA-approved blood-based option for average-risk adults who decline traditional colorectal screening methods. Against that product backdrop, Abbott Laboratories has seen its 1 month share price return fall about 10.2%, while the 90 day share price return is up 9.5%. This points to fading short term momentum compared with a still positive multi quarter trend. Recent...

La fiscal general de Mississippi, Lynn Fitch, anunció un acuerdo de 384 millones de dólares con Abbott Laboratories por acusaciones de que la empresa defraudó a programas de salud gubernamentales al vender fórmulas infantiles y productos de terapia nutricional elaborados a partir de plantas que no cumplían con las normas de seguridad estatales y federales. Fitch anunció el acuerdo junto con otros 39 estados y…

Abbott Laboratories stock was at EUR 87.96 in after-hours trading at 7:42 p.m. CEST on September 30,